Latest news with #AlkemLaboratories
News18
5 days ago
- Automotive
- News18
Mumbai's Wealthy Businessman With Links To Bihar: Owner Of Rs 12 Crore Luxury Rolls-Royce Car Is…
Last Updated: Naval Kishore Singh, son of Samprada Singh, owns the most expensive Rolls-Royce in India, a Cullinan worth Rs 12 crores. Rolls-Royce is synonymous with refined luxury. This British multinational aerospace and defence company is known for its world-class aero‑engines, marine propulsion systems, and power-generation technology. It is not often that you will see someone deciding to buy a Rolls-Royce one day and bringing the car back home the next day. The price range of this luxurious vehicle starts from approximately Rs 7 crore. But do you know who owns the most expensive Rolls-Royce in India? Well, he is none other than the son of Samprada Singh — the owner of Alkem Pharmaceutical Company, one of the top pharmaceutical companies in the world. According to a report by Samprada Singh's eldest son, Naval Kishore Singh, owns the most luxurious Rolls-Royce in India. He recently purchased a swanky Rolls-Royce Cullinan at a price of Rs 12 crores. The vehicle is a part of the Rolls-Royce Cullinan Series II, which was launched last year. The ex-showroom price of the Black Badge Rolls‑Royce Cullinan Series II is approximately Rs 12.25 crore. One of the special features of the Rolls-Royce Cullinan is that it has a 6.75‑liter twin‑turbo V12 engine. It also pumps out an impressive 900 Nm of torque. Coming to Samprada Singh, his firm, Alkem Pharmaceutical Company, is running in over 20 countries including Asia, Africa and Europe. Samprada Singh, a resident of Okri village in Jehanabad district, Bihar, established Alkem Laboratories in Mumbai in 1973. He was joined by his brother in the venture. Later, the family shifted to Mumbai. Samprada Singh was born in 1925 and earned a degree from Patna University. A few years later, in 1953, he opened a small chemist shop at the PMCH area in Patna and then founded Magadh Pharma to distribute medicines across Bihar. Samprada Singh co-founded Alkem Laboratories with his brother in Mumbai in 1973. Samprada Singh passed away on July 27, 2019. He was 94. The industrialist breathed his last at Lilavati Hospital in Mumbai. He was reportedly suffering from an illness. First Published: June 17, 2025, 14:28 IST
Business Upturn
04-06-2025
- Business
- Business Upturn
Alkem Labs shares trade lower after Rs 856 crore block deal
By Aditya Bhagchandani Published on June 4, 2025, 09:31 IST Shares of Alkem Laboratories came into focus on Tuesday following a large block deal worth ₹856.39 crore executed on the BSE. The transaction involved the exchange of approximately 17.49 lakh shares at a price of ₹4,895.60 per share. Ahead of the trade, reports had indicated that Jayanti Sinha, a member of the promoter group, was planning to offload a 1.42% stake in the company. As per the March 2025 shareholding data, Sinha held a 2.46% stake in Alkem Laboratories. The block deal, executed at a floor price of ₹4,850, was offered at a nearly 3% discount to the last traded price. Promoters hold a controlling 55.1% stake in Alkem, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) own 9.4% and 19.4% stakes respectively. The public holds the remaining 16.1% of the equity. Financially, Alkem Labs reported a 4.2% year-on-year increase in net profit to ₹305.9 crore for the March quarter. Revenue rose 7.1% to ₹3,143.8 crore, but EBITDA margins saw a decline to 12.4% from 13.7% last year, leading to some investor disappointment. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Time of India
04-06-2025
- Business
- Time of India
I-Sec maintains Add on Alkem Laboratories, revises target price to Rs 5,900
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel ICICI Securities maintains an Add call on Alkem Laboratories with a revised target price of Rs 5,900 (earlier Rs 5,920). The current market price of Alkem Laboratories is Rs 5065.15. Alkem Laboratories, incorporated in 1973, is a Large Cap company with a market cap of Rs 61014.02 crore, operating in the pharmaceuticals Laboratories' key products/revenue segments include Pharmaceuticals, Other Operating Revenue, Export Incentives and Scrap for the year ending the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 3289.71 crore, down -5.12 % from last quarter Total Income of Rs 3467.27 crore and up 8.79 % from last year same quarter Total Income of Rs 3023.99 crore. The company has reported net profit after tax of Rs 323.01 crore in the latest company?s top management includes N Singh, Ravi, Singh, Kumar Purwar, Talwar, Singh, Kumar Singh, Singh, Singh, Singh, Kumar Aneja. Company has BSR & Co. LLP as its auditors. As on 31-03-2025, the company has a total of 12 crore shares Securities expects Alkem to witness revenue CAGR of 9.3% and nominal margin expansion of ~50bps to 19.9% over FY25-27E. They have reduced EPS by ~27% for FY27E to factor in higher tax rate. The stock trades at valuations of 27.3x FY26E and 33.0x FY27E earnings and EV/EBITDA multiple of 21.8x FY26E and 19.1x FY27E. The brokerage maintains ADD with lower target price of Rs 5,900 (earlier Rs 5,920) based on 22x FY27E EV/EBITDA (29x FY26E earnings earlier). Key downside risks include more products under price control, regulatory lapses in US-centric plants and slowdown in trade held 55.13 per cent stake in the company as of 31-Mar-2025, while FIIs owned 9.4 per cent, DIIs 19.42 per cent.
Economic Times
04-06-2025
- Business
- Economic Times
I-Sec maintains Add on Alkem Laboratories, revises target price to Rs 5,900
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel ICICI Securities maintains an Add call on Alkem Laboratories with a revised target price of Rs 5,900 (earlier Rs 5,920). The current market price of Alkem Laboratories is Rs 5065.15. Alkem Laboratories, incorporated in 1973, is a Large Cap company with a market cap of Rs 61014.02 crore, operating in the pharmaceuticals Laboratories' key products/revenue segments include Pharmaceuticals, Other Operating Revenue, Export Incentives and Scrap for the year ending the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 3289.71 crore, down -5.12 % from last quarter Total Income of Rs 3467.27 crore and up 8.79 % from last year same quarter Total Income of Rs 3023.99 crore. The company has reported net profit after tax of Rs 323.01 crore in the latest company?s top management includes N Singh, Ravi, Singh, Kumar Purwar, Talwar, Singh, Kumar Singh, Singh, Singh, Singh, Kumar Aneja. Company has BSR & Co. LLP as its auditors. As on 31-03-2025, the company has a total of 12 crore shares Securities expects Alkem to witness revenue CAGR of 9.3% and nominal margin expansion of ~50bps to 19.9% over FY25-27E. They have reduced EPS by ~27% for FY27E to factor in higher tax rate. The stock trades at valuations of 27.3x FY26E and 33.0x FY27E earnings and EV/EBITDA multiple of 21.8x FY26E and 19.1x FY27E. The brokerage maintains ADD with lower target price of Rs 5,900 (earlier Rs 5,920) based on 22x FY27E EV/EBITDA (29x FY26E earnings earlier). Key downside risks include more products under price control, regulatory lapses in US-centric plants and slowdown in trade held 55.13 per cent stake in the company as of 31-Mar-2025, while FIIs owned 9.4 per cent, DIIs 19.42 per cent.
Bloomberg
04-06-2025
- Business
- Bloomberg
Indian Stocks Bullish Momentum Takes a Pause
Before the trading day starts we bring you a digest of the key news and events that are likely to move markets. Today we look at: Good morning, this is Chiranjivi Chakraborty, an equities reporter in Mumbai. Nifty futures point to a firm start for Indian equities this morning after three straight days of losses. Buoyant Asian stocks are likely to support gains in local shares. Meanwhile, more block deals are expected today, with founders and strategic investors in companies including Tata Technologies, Aditya Birla Fashion and Alkem Laboratories continuing to cash in on rich valuations.
